Mesterolone 25 - Androlex

First marketed in 1934 by Schering as Proviron®, Mesterolone represented a cornerstone in early androgen therapy. It appeared before key injectable esters and offered a rare oral option for treating male hypogonadism at the time. With limited anabolic potential but strong androgenic expression, it maintained relevance in clinical endocrinology across Europe for decades. Its low tendency to convert to estrogen or suppress the pituitary axis made it suitable for long-term hormone support, even beyond Schering’s merger with Bayer.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Mesterolone 25 by Androlex, consult with your doctor or healthcare professional.